In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Pancragen (KEDW) | Synthetic analog Liraglutide | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Weight and metabolic | Weight and metabolic | |
| Evidence | |||
| Amount of evidence | 35 | 4,766 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | No safety results | 805 (793 in people) | |
| Status | |||
| Approval | Not recorded | ||
| Sport (WADA) | |||
| Registered trials | None registered | 469 · 30 active49 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Pancragen (KEDW) | Liraglutide |
|---|---|---|
| Glycemic controlMetabolic and weight | 15510 | 1,1171067491 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The EMA label for Victoza says: “Adults, adolescents and children 10 years and older with insufficiently controlled type 2 diabetes, as an adjunct to diet and exercise”
| Receptor activity and mechanismEndocrine and hormones | 19217 | 8250626 |
|---|
| Cardiometabolic risk factorsCardiovascular | 11 | 3030 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Liraglutide differs from Glucagon-like peptide 1 (7-37) at 1 position and carries 1 added group.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Pancragen (KEDW) | Liraglutide |
|---|---|---|
| Glycemic controlMetabolic and weightCompared as: difference from placebo, in % | No randomized trial result 15 results from other study designs. | −1.09% HbA1c difference Dose studied: 1.8 mg once daily26 weeksn = 3442009 |
| Cardiometabolic risk factorsMetabolic and weightCompared as: difference from placebo, in % | No randomized trial result 1 result from other study designs. | −4% MR-proADM reduction · Shown as a change. The study reports a mr-proadm reduction of this size. Dose studied: 1.8 mg/d12 weeksn = 272017 |
| Receptor activity and mechanismCardiovascularCompared as: difference from placebo, in proteins | No randomized trial result 19 results from other study designs. | 124 proteins Proteins modulated Dose studied: 3 mg daily5 weeksn = 202026 |
No randomized trial result
15 results from other study designs.
−1.09%
HbA1c difference
Dose studied: 1.8 mg once daily26 weeksn = 3442009
No randomized trial result
1 result from other study designs.
−4%
MR-proADM reduction · Shown as a change. The study reports a mr-proadm reduction of this size.
Dose studied: 1.8 mg/d12 weeksn = 272017
No randomized trial result
19 results from other study designs.
124 proteins
Proteins modulated
Dose studied: 3 mg daily5 weeksn = 202026
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
No registered trial that tests Pancragen (KEDW) found in ClinicalTrials.gov.
Top 3 of 469 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S9,341 participants31 Aug 2010 to 17 Dec 2015
Diabetes · Diabetes Mellitus, Type 2
GRADE Study Group7,850 participantsMay 2013 to 30 Apr 2021
Type 2 Diabetes · Comparative Effectiveness of Glycemia-lowering Medications
Novo Nordisk A/S3,731 participants1 Jun 2011 to 2 Mar 2015
Metabolism and Nutrition Disorder · Obesity
49 more mention it but do not test it. They only measure it or name it in their text.